Bevacizumab Approved for Metastatic Renal Cell Carcinoma

Publication
Article
OncologyONCOLOGY Vol 23 No 9
Volume 23
Issue 9

Genentech announced that the US Food and Drug Administration (FDA) has approved bevacizumab (Avastin) plus interferon- alfa for people with metastatic renal cell carcinoma, the most common type of kidney cancer.

Genentech announced that the US Food and Drug Administration (FDA) has approved bevacizumab (Avastin) plus interferon-alfa for people with metastatic renal cell carcinoma, the most common type of kidney cancer. Kidney cancer is the eighth most commonly diagnosed cancer in the United States. In 2009, 13,000 Americans will die from the disease.

“During the last 5 years, Avastin has been approved by the FDA to treat five different types of cancer,” said Hal Barron, MD, executive vice president, Global Development and chief medical officer, Genentech. “We aim to help more people facing difficult-to-treat cancers and will continue studying Avastin in more than 30 other tumor types.”

Recent Videos
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Rohit Gosain, MD; Sumanta Kumar Pal, MD, FASCO; and Rahul Gosain, MD, presenting slides
Rohit Gosain, MD; Sumanta Kumar Pal, MD, FASCO; and Rahul Gosain, MD, presenting slides
Rohit Gosain, MD; Sumanta Kumar Pal, MD, FASCO; and Rahul Gosain, MD, presenting slides
Rohit Gosain, MD; Sumanta Kumar Pal, MD, FASCO; and Rahul Gosain, MD, presenting slides
Related Content